US President Trump Was Provided a Single 8-Gram Dose of REGN-COV2

New York based Regeneron Pharmaceuticals, Inc. confirmed that the company provided a single 8-gram dose of REGN-COV2, a cocktail of two monoclonal antibodies, for use by the U.S. President Donald J. Trump.

REGN-COV2 is an investigational COVID-19 therapy, which was provided in response to an Individual Patient Investigational New Drug application, commonly known as ‘compassionate use’ request, from the President’s physicians. In the USA, this type of compassionate use program is also known as an Expanded Access Program and is intended for patients with serious or life-threatening conditions who do not have any viable or available treatment options and are unable to participate in ongoing clinical trials.

Regeneron is accelerating the traditional drug development process through its proprietary technologies that use unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.